A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer
Status:
Terminated
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This study is being offered to patients who have hormone resistant prostate cancer (HRPC).
This means that their prostate cancer is no longer responding to standard hormonal therapy.
The purpose of this study is to determine whether Degarelix will be able to stop the PSA from
rising in patients with hormone resistant prostate cancer.